Glivec
Novartis ends phase III trial of Tasigna
April 12, 2011GIST, Glivec, Novartis, Tasigna
Novartis has stopped a late stage study of Tasigna for certain types of stomach cancers after it failed to show …
Trial hitch for Pfizer’s leukaemia drug submission plans
December 7, 2010Research and Development, Sales and Marketing CML, Gleevec, Glivec, Pfizer, bosutinib, chronic myeloid leukaemia
Pfizer is pressing ahead with plans to submit bosutinib for European approval despite the chronic myeloid leukaemia drug missing its …
NICE recommends Herceptin for gastric cancer, blocks high dose Glivec
November 24, 2010Sales and Marketing Cancer, GIST, Glivec, HER2, Herceptin, NICE, gastric cancer
NICE has recommended Roche’s cancer drug Herceptin for patients with HER2 metastatic gastric cancer. NICE was initially minded not to …
NICE rejects Glivec as adjuvant therapy
June 24, 2010Sales and Marketing Glivec, NICE, Novartis
NICE has rejected the use of Novartis’ Glivec as an adjuvant treatment for people who have had a gastrointestinal stromal …
Tasigna more effective than Glivec, says Novartis
June 21, 2010Research and Development, Sales and Marketing Glivec, Novartis, Tasigna, leukaemia
Novartis has gained US approval for Tasigna to be used as a front line treatment for chronic myeloid leukaemia. The …
NICE seeks compromise over Glivec approval
March 24, 2010Sales and Marketing Glivec, NICE, Novartis
NICE says it is unlikely to approve the use of Glivec against gastrointestinal stromal tumours (GISTs) after surgery, but is …
Latest content
Five Facts about cardiovascular disease
